T
T. Ishii
Researcher at Eli Lilly and Company
Publications - 10
Citations - 920
T. Ishii is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Rheumatoid arthritis & Context (language use). The author has an hindex of 7, co-authored 10 publications receiving 674 citations.
Papers
More filters
Journal ArticleDOI
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor,Edward C. Keystone,Désirée van der Heijde,Michael E. Weinblatt,Liliana del Carmen Morales,Jaime Reyes Gonzaga,Sergey Yakushin,T. Ishii,K. Emoto,Scott Beattie,Vipin Arora,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,William L. Macias,Stephanie de Bono,Yoshiya Tanaka +16 more
TL;DR: In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.
Journal ArticleDOI
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S Smolen,Mark C. Genovese,Tsutomu Takeuchi,David L. Hyslop,William L. Macias,Terence Rooney,L. Chen,C. Dickson,Jennifer Riddle Camp,Tracy Cardillo,T. Ishii,Kevin L. Winthrop +11 more
TL;DR: In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.
Journal ArticleDOI
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai,Tsutomu Takeuchi,Josef S Smolen,Kevin L. Winthrop,Atsushi Nishikawa,Terence Rooney,Chadi Saifan,Maher Issa,Yoshitaka Isaka,Naotsugu Akashi,T. Ishii,Yoshiya Tanaka +11 more
TL;DR: In Japanese patients, herpes zoster was more frequent than that of patients overall in the integrated database, but the events were considered manageable, and baricitinib had acceptable safety profile in Japanese RA patients in the context of demonstrated efficacy.
Journal ArticleDOI
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
TL;DR: The efficacy and safety profile of baricitinib was maintained during long-term treatment of Japanese patients with RA and background methotrexate therapy and increases in the American College of Rheumatology response rates observed during the first 12 weeks were maintained during the extension period.
Journal ArticleDOI
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Yoshiya Tanaka,Tatsuya Atsumi,Koichi Amano,Masayoshi Harigai,T. Ishii,Osamu Kawaguchi,Terence Rooney,Naotsugu Akashi,Tsutomu Takeuchi +8 more
TL;DR: Data for baricitinib, with/without methotrexate, in Japanese subpopulations across all stages of the RA treatment continuum accord with the efficacy/safety profile in overall study populations.